BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.